Pfizer’s $68 billion acquisition of Wyeth last year has turned into a full-employment act for the drugmaker’s outside law firms.
Yesterday the company was slapped with a whistleblower lawsuit alleging Wyeth detailers promoted the off-label use of the immunosuppressant drug Rapamune for kidney transplant patients even though the Food and Drug Administration has explicitly warned about serious side effects and increased mortality associated with switching them from safer drugs. According to Jim Edwards’ report on Bnet, the complaint alleges African-Americans were specifically targeted by salesmen since they are considered “high-risk” patients due to their higher organ rejection rates.
Continue Reading
